Literature DB >> 16282149

Acute retinal necrosis.

Adriana A Bonfioli1, Andrew W Eller.   

Abstract

Acute retinal necrosis (ARN) is an uncommon intraocular inflammatory syndrome characterized by severe and diffuse uveitis, retinal vasculitis, and retinal necrosis. It is typically described to occur in immunocompetent patients, but can also be found in immunocompromised subjects. Varicella-zoster virus (VZV), herpes simplex virus (HSV 1 and 2), cytomegalovirus (CMV), and Epstein-Barr virus (EBV) have been implicated in the etiology of ARN. The characteristic features of the disease include iridocyclitis, vitritis, retinal vasculitis, and retinal necrosis. Bilateral involvement occurs in two-thirds of the patients, frequently in the first six weeks, but sometimes months to years later. Retinal detachment occurs in 75% of the cases. The diagnosis of ARN is usually based in clinical features. The use of polymerase chain reaction (PCR) in aqueous humor samples is useful to identify the etiology of the disease. The treatment of ARN includes intravenous acyclovir, corticosteroids and aspirin. To prevent fellow eye involvement, intravenous acyclovir is followed by oral acyclovir for 14 weeks. Alternatives to acyclovir include ganciclovir, foscarnet, famcyclovir, brivudine, and valgancyclovir.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282149     DOI: 10.1080/08820530500232027

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  15 in total

Review 1.  Review: The neurobiology of varicella zoster virus infection.

Authors:  D Gilden; R Mahalingam; M A Nagel; S Pugazhenthi; R J Cohrs
Journal:  Neuropathol Appl Neurobiol       Date:  2011-08       Impact factor: 8.090

2.  Advances in the Diagnosis and Management of Acute Retinal Necrosis.

Authors:  Casey L Anthony; J Clay Bavinger; Steven Yeh
Journal:  Ann Eye Sci       Date:  2020-09-15

3.  [Intravitreal ganciclovir as an additional therapy option in acute retinal necrosis].

Authors:  M Bischoff-Jung; A Viestenz; M Fiorentzis; L Daas; B Seitz; G Pappas; A Viestenz
Journal:  Ophthalmologe       Date:  2017-09       Impact factor: 1.059

Review 4.  Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia.

Authors:  D Gilden
Journal:  J Intern Med       Date:  2011-02-23       Impact factor: 8.989

5.  Clinical and molecular aspects of varicella zoster virus infection.

Authors:  Don Gilden; Maria A Nagel; Ravi Mahalingam; Niklaus H Mueller; Elizabeth A Brazeau; Subbiah Pugazhenthi; Randall J Cohrs
Journal:  Future Neurol       Date:  2009-01-01

Review 6.  Varicella-zoster.

Authors:  Don Gilden; Maria A Nagel; Randall J Cohrs
Journal:  Handb Clin Neurol       Date:  2014

Review 7.  Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency.

Authors:  Niklaus H Mueller; Donald H Gilden; Randall J Cohrs; Ravi Mahalingam; Maria A Nagel
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

Review 8.  Intraocular inflammation: its causes and investigations.

Authors:  Claire Hooper; Peter McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.919

9.  Complications of varicella zoster virus reactivation.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.972

10.  Clinically applicable artificial intelligence algorithm for the diagnosis, evaluation, and monitoring of acute retinal necrosis.

Authors:  Lei Feng; Daizhan Zhou; Chenqi Luo; Junhui Shen; Wenzhe Wang; Yifei Lu; Jian Wu; Ke Yao
Journal:  J Zhejiang Univ Sci B       Date:  2021-06-15       Impact factor: 3.066

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.